Does Rallies show Form 4 insider transactions for DAWN?

Yes. Rallies tracks DAWN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DAWN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DAWN. It does not provide personalized investment advice.

DAWN (Day One Biopharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Day One Biopharmaceuticals, Inc. Common Stock (DAWN) is a publicly traded Healthcare sector company. As of May 21, 2026, DAWN trades at $21.53 with a market cap of $2.22B and a P/E ratio of -20.70. DAWN moved +0.14% today. Year to date, DAWN is +158.15%; over the trailing twelve months it is +193.72%. Its 52-week range spans $5.64 to $21.53. Analyst consensus is buy with an average price target of $23.75. Rallies surfaces DAWN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DAWN stock inside the company?

Recent DAWN insider activity includes Merendino Lauren sold 5.81K, Dubow Adam sold 6.39K, York Charles N II sold 6.07K, Bender Jeremy sold 15.46K, and VASCONCELLES MICHAEL sold 2.73K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DAWN Key Metrics

Key financial metrics for DAWN
Metric	Value
Price	$21.53
Market Cap	$2.22B
P/E Ratio	-20.70
EPS	$-1.04
Dividend Yield	0.00%
52-Week High	$21.53
52-Week Low	$5.64
Volume	2.99M
Avg Volume	0
Revenue (TTM)	$158.18M
Net Income	$-107.32M
Gross Margin	0.00%

Recent DAWN Insider Trades

Merendino Lauren sold 5.81K (~$67.45K) on Feb 17, 2026.
Dubow Adam sold 6.39K (~$74.19K) on Feb 17, 2026.
York Charles N II sold 6.07K (~$70.36K) on Feb 17, 2026.
Bender Jeremy sold 15.46K (~$179.34K) on Feb 17, 2026.
VASCONCELLES MICHAEL sold 2.73K (~$31.65K) on Feb 17, 2026.

Latest DAWN News

Day One Biopharma Faces Fiduciary Probe Over $21.50 Per Share Servier Sale — Apr 9, 2026
Day One Biopharma Guides to $225M-$250M in 2026 on $155M 2025 Revenue — Mar 9, 2026
Day One Biopharmaceuticals to Merge for $2.5 Billion at $21.50 Share Price — Mar 7, 2026
Day One Biopharmaceuticals Posts Narrower $0.20 Loss, 11.4% Q4 Revenue Beat — Feb 25, 2026
Day One Shares Jump 26.7% as OJEMDA Treats 1,000+ Children, Yet Estimates Cut — Jan 13, 2026

DAWN Analyst Consensus

12 analysts cover DAWN: 0 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $23.75.

Common questions about DAWN

Who is trading DAWN stock inside the company?: Recent DAWN insider activity includes Merendino Lauren sold 5.81K, Dubow Adam sold 6.39K, York Charles N II sold 6.07K, Bender Jeremy sold 15.46K, and VASCONCELLES MICHAEL sold 2.73K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DAWN?: Yes. Rallies tracks DAWN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DAWN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DAWN. It does not provide personalized investment advice.